Get the Daily Brief
Latest Biotech News
Two CAR‑T moves narrow the gap to solid tumors: checkpoint deletion and ultra‑sensitive receptors
Researchers reported two advances aimed at overcoming key barriers to CAR‑T efficacy in solid tumors. One study showed that deletion of the nuclear receptor NR2F6 can reinvigorate exhausted CAR‑T...
Gut microbes reshape cancer therapy — mechanistic link and new microbiome metric
A high‑profile Science report linking the gut microbiome to PD‑1 immunotherapy outcomes received recognition with a Bial Award, while independent work introduced an ecological network balance...
BreezeBio lands $60M to convert delivery tech into internal mRNA pipeline
BreezeBio (formerly Genedit) closed a $60 million financing to shift from an open delivery platform to building an internal pipeline anchored by its Nanogalaxy delivery technology. The round funds...
FDA floats rapid pathways for rare and ultra‑rare therapies
The FDA published draft guidance outlining a 'Plausible Mechanism' framework and a complementary ultra‑rare therapies pathway to accelerate development of highly personalized genomic and...
Sequencing price and throughput battle heats up: Roche’s $150 genome vs Ultima’s UG200
At AGBT, Roche disclosed pricing and performance details for its Axelios 1 sequencing platform, claiming a $150 cost for a 30× human genome and a $750,000 list price for the instrument. The...
Astellas, Vir tie up on masked TCE — up to $1.7B for prostate program
Astellas entered a co‑development and co‑commercialization agreement with Vir Biotechnology for VIR‑5500, a PSMA‑targeted, PRO‑XTEN masked T‑cell engager for prostate cancer, in a deal potentially...
Novo Nordisk Commits $2.1B to Oral Biologics – Vivtex Deal
Novo Nordisk has struck a strategic collaboration with Vivtex to develop oral formulations of peptide and protein therapeutics for obesity, diabetes and related metabolic disorders. The agreement...
Sequencing Price War: Roche’s $150 Genome and Ultima’s UG200 Launch
Two sequencing suppliers unveiled aggressive commercial moves at AGBT that compress cost and expand throughput. Roche disclosed pricing and workflow details for its Axelios 1 sequencing platform,...
Mutant p53 Reactivation Shows Clinical Activity – Rezatapopt in NEJM
PMV Pharmaceuticals published Phase I first‑in‑human data for rezatapopt in the New England Journal of Medicine showing objective responses in heavily pretreated patients with TP53 Y220C‑mutated...
CAR‑T Reboot: NR2F6 Deletion and Ultra‑Sensitive Cells Target Solids
Two independent research advances unveiled strategies to overcome barriers to CAR‑T efficacy in solid tumors. One study reports that deletion of the nuclear receptor NR2F6 — an intrinsic...
GSK Expands Pulmonary and RNA Plays: 35Pharma Buy and Frontier siRNA Deal
GSK is consolidating respiratory and RNA capabilities through two transactions. The company agreed to acquire 35Pharma for $950 million in cash, adding HS235 — a clinical‑stage activin‑signaling...
Asahi Kasei Buys Aicuris for $920M to Bulk Up Antiviral R&D
Asahi Kasei agreed to acquire Aicuris Anti‑infective Cures AG for €780 million (about $920 million) to expand its infectious‑disease portfolio. The acquisition brings marketed letermovir...
FDA Proposes 'Plausible Mechanism' and Ultra‑Rare Frameworks — Faster Paths
The FDA released draft guidance frameworks aimed at accelerating development of personalized and ultrarare therapies. The 'plausible mechanism' concept would let developers advance individualized...
FDA Under Fire: Senators and Advocates Challenge Rare‑Disease Rejections
A high‑profile Senate hearing and related public testimony put the FDA’s rare‑disease review record under scrutiny. Clinicians, patient advocates and company leaders testified that inconsistent...
BreezeBio Shifts to Internal Pipeline After $60M Raise
BreezeBio (formerly Genedit) closed a $60 million financing to pivot its Nanogalaxy delivery platform into an internal therapeutic pipeline. The company said it will fund lead programs toward...
Lex Diagnostics Starts Commercialization of 10‑Minute POC qPCR
Lex Diagnostics began commercial rollout of Velo, a point‑of‑care qPCR platform that secured FDA 510(k) clearance and a CLIA waiver for a flu/COVID cartridge. Velo performs true sample‑to‑answer,...
p53 pocket drug rezatapopt yields responses in Y220C tumors — NEJM
Researchers published Phase I first-in-human data for rezatapopt in the New England Journal of Medicine showing objective responses in heavily pretreated patients whose tumors harbor the TP53...
FDA voucher speeds Boehringer label expansion for HER2 lung cancer
The FDA used a National Priority Voucher to accelerate review and approve Boehringer Ingelheim’s oral drug Hernexeos as a first‑line treatment for HER2‑positive non‑small cell lung cancer. The...
Novo Nordisk inks up-to-$2.1B deal to get Vivtex oral biologics tech
Novo Nordisk agreed to license Vivtex’s gastrointestinal screening and formulation platform in a deal potentially worth up to $2.1 billion plus tiered royalties to pursue oral peptide and protein...
Astellas to co‑develop Vir’s masked T‑cell engager for prostate cancer — $1.7B
Astellas Pharma and Vir Biotechnology struck a co‑development and co‑commercialization agreement focused on VIR‑5500, a masked T‑cell engager (TCE) targeting PSMA for prostate cancer. The deal...